Minerva Surgical, Inc. revised revenue guidance for the year 2022. Due to the ongoing impacts of COVID-19 on elective ablation procedures, annual revenue guidance for 2022 is being reduced to a range of $50 million to $53 million. Sales revenue has been significantly impacted over the past two years, including the first two quarters of 2022, by both government and hospital restrictions on elective surgeries in select markets and staffing challenges at hospitals.